retatrutide Clinical Trial Data and the Phase 2 Record
This page files the published retatrutide clinical trial data as a structure rather than as a set of headline numbers. A trial record has moving parts: a cohort definition, randomisation, a dose escalation schedule, week marks at which endpoints are read, and a set of adverse event counts with discontinuation proportions. Reading any single figure without those parts is how a phase 2 result turns into a claim that the publication never made.
The obesity programme is the anchor here. The phase 2 cohort was dose-ranging and randomised against placebo, and it was carried to a later time point than the primary endpoint, which is why two week marks appear in most summaries of retatrutide clinical trial data. A separate hepatic steatosis cohort is reported with its own endpoints and should not be merged into the obesity figures.
retatrutide has no full fda approval and remains investigational, and every figure below is a cohort-level result rather than a prediction for any individual. Community threads describe this anecdotally; the report is not verified clinical data. The reading room index at retatrutide reddit collects the rest of the notes, and this page deliberately avoids any statement about what a reader should do with the numbers.
Phase 2 cohort structure in the retatrutide clinical trial data
The phase 2 obesity cohort was randomised, placebo-controlled and dose-ranging, enrolling several hundred participants across a placebo arm and a range of dose arms. Enrolment carried a bmi threshold, and in the reported design the main obesity cohort enrolled adults obese by bmi without a diabetes diagnosis. Arms were escalated rather than opened at the final dose, and the escalation pace was part of the protocol.
Cohort structure is the first thing to check in any retatrutide clinical trial data summary, because it fixes what the figures can be generalised to. Several hundred participants over roughly a year is enough to estimate a body-weight change direction under protocol conditions and not enough to characterise uncommon events. The cohort also skews by recruitment channel, which limits external generalisability further.
Week marks and why two time points get quoted
The primary endpoint in the obesity phase 2 report was read at week 24, and the cohort was then carried to week 48 with body-weight change reported at that later mark as well. Both numbers circulate and they are frequently mixed. A week 24 figure answers the protocol question; a week 48 figure describes the trajectory among participants who remained on the assigned dose under study conditions.
Trajectory is not the same as durability. At the later time point the cohort is smaller because of discontinuation, and the analysis handles missing records by a stated method rather than by observation. Any comparison drawn from retatrutide clinical trial data has to name the week mark, the estimand and whether the analysis population was everyone randomised or only those remaining on the assigned dose, or it is comparing two different questions.
Endpoint definitions: primary, secondary and exploratory
The primary endpoint in the obesity cohort was percentage change in body weight from baseline. Secondary endpoints covered cardiometabolic measures: waist circumference, blood pressure, glycated haemoglobin, fasting glucose and lipids. Exploratory measures included hepatic fat in the substudy. Each tier carries a different statistical status, and exploratory findings are hypothesis-generating rather than confirmatory.
The distinction matters for reading. A primary endpoint is declared before the cohort is read and carries the trial's statistical plan. Secondary endpoints share the plan but not the power. Exploratory endpoints are reported with the awareness that multiplicity makes any single striking value unreliable. Community summaries routinely promote exploratory numbers to primary status, which is a structural error rather than a difference of opinion.
Body weight reduction figures as published
The published figures are percentage changes from baseline, reported as least-squares means with confidence intervals, and they rise with dose across the arms. At the week 24 mark the highest doses reported reductions in the high-teens percent range against a placebo arm near two percent. At week 48 the highest dose arm was reported above twenty percent, with the placebo arm again near two percent.
Two cautions attach to those numbers. They are means over a cohort, so the spread around them is wide and an individual result is not predicted by the mean. And the arms are not independent contrasts against each other: the protocol compares each dose arm with placebo, not with the neighbouring dose. Any ranking between two active arms is descriptive rather than a tested contrast in the published retatrutide clinical trial data.
| week mark | cohort | reported body-weight change | comparator |
|---|---|---|---|
| week 24 | phase 2 obesity cohort, dose-ranging | high-teens percent range at the highest doses | placebo arm near two percent |
| week 48 | same cohort carried to the later time point | above twenty percent at the highest dose | placebo arm near two percent |
| separate readout | phase 2 hepatic steatosis cohort | liver fat endpoint, reported separately | placebo arm, own cohort |
Adverse event counts and discontinuation proportions
The adverse event profile reported in the phase 2 cohort is dominated by gastrointestinal events: nausea, vomiting, diarrhoea and constipation, reported more often in the active arms than in placebo and more often at higher doses and during escalation. Most events were graded mild to moderate in severity. The published record also reports increases in pulse rate and a small set of events that led to withdrawal.
Discontinuation is the number worth reading closely. Discontinuation owing to adverse events rose with dose, reaching roughly the mid-teens in percentage terms at the highest dose in the obesity cohort against a lower figure in placebo. Overall discontinuation including other reasons is higher still. Those proportions change the reading of the later week mark, because the cohort read at week 48 is not the cohort randomised at baseline.
Dose escalation and the gastrointestinal signal
The escalation schedule is part of the design rather than a footnote. Arms opened at a low dose and stepped upward over the first weeks to a maintenance dose. Escalation is standard practice with incretin-class compounds because the gastrointestinal signal is dose-related, and the published event counts describe a cohort that was titrated rather than one exposed to the final dose from the first day.
That has a direct consequence for anyone comparing event rates across programmes. Two compounds with different escalation speeds will report different gastrointestinal counts even at identical receptor potency, because the exposure ramp differs. This is one reason adverse event tables from separate programmes do not sit on a common scale, and it applies within retatrutide clinical trial data as much as it does across programmes.
Cardiometabolic secondary measures reported
The secondary set reported reductions in waist circumference and changes in blood pressure, glycated haemoglobin, fasting glucose and triglyceride measures across active arms relative to placebo. These are consistent in direction with the body-weight change and with the known behaviour of incretin-class compounds. They are reported with confidence intervals and without claims about event reduction.
No outcome trial has been reported for this compound. A body-weight change plus a set of cardiometabolic intermediates are surrogate measures; they are not the same as a demonstration that cardiovascular events fall. That distinction is the single most common omission in community summaries, and it is the reason surrogate endpoints are filed here as surrogates rather than as outcomes.
The hepatic steatosis cohort is reported separately
A separate phase 2 cohort enrolled participants with hepatic steatosis and reported liver fat as the endpoint, with large relative reductions reported at the doses studied. That cohort has its own size, its own baseline characteristics and its own endpoint, and the figures should not be appended to the obesity cohort as though both came from one study.
Separateness matters because the two cohorts answer different questions. One asks what happens to body weight in an obesity cohort; the other asks what happens to liver fat in a hepatic cohort. A reader who merges them produces a composite that no publication reports, and the merged figure then circulates as though it were a single result.
What a registry entry does and does not establish
A registry entry is a declaration made before or during enrolment: design, cohort size, endpoints, arms and status. It is the most underused document attached to retatrutide clinical trial data because it fixes the question before the answer exists, which is exactly what makes it useful for checking whether a published result matches what was planned.
It is also limited. A registry entry does not establish that endpoints were met, does not carry results unless results are posted, and can be amended. Version history is part of the record. The bullets below separate what a registry entry settles from what only a publication can settle.
- A registry entry establishes that a study was registered with a declared cohort size and endpoint set.
- It does not establish that the declared endpoints were met; that requires the publication.
- It does not establish generalisability beyond the enrolled cohort and its entry criteria.
- Amendments are part of the record, so the version date matters as much as the design.
- It does not establish anything about a compound outside the registered protocol and dose schedule.
How this page is filed
This note is filed under retatrutide reddit clinical research with the mechanism note and the comparison note. The reading room index at retatrutide reddit collects the full set. Pages here paraphrase public community discussion and summarise published research without recommending any course of action.
Numbers on this page are dated. Cohort sizes, week marks and event proportions are fixed by publication, but programme status is not, and later phase 3 readouts will supersede the phase 2 figures. The registry searches listed at the bottom are the version of record for what is currently registered.
Frequently asked questions
How large was the phase 2 cohort?
Several hundred participants across the dose arms and placebo. That is enough to estimate a direction for body weight change under protocol conditions and not enough to characterise uncommon events. Cohort size is stated in the publication and in the registry entry.
Which week mark should be quoted?
Both the week 24 and week 48 marks are published, and they answer slightly different questions. Quote the week mark with the figure. A number without a time point, an estimand and an analysis population is not comparable to anything.
Do the adverse event counts include everyone randomised?
Event counts in the publication are generally reported for participants who received at least one dose. Discontinuation proportions are reported separately, and the week 48 cohort is smaller than the randomised cohort because of those withdrawals.
Are the body weight reduction figures individual results?
No. They are cohort means reported as least-squares means with confidence intervals. The spread around the mean is wide, and a cohort mean does not predict an individual outcome.
Does a registry entry mean the result is established?
No. A registry entry records a design, not a result. Community threads describe this anecdotally; the report is not verified clinical data.
Neutral reference searches
Registry, literature and public-record search links. None of them confirms or denies any claim filed elsewhere on this site.